Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Breast Cancer

Free Subscription Articles published in Exp Cell Res Retrieve available abstracts of 19 articles: HTML format Text format

Single Articles

May 2019
1. FOURIE C, Davis T, Kriel J, Engelbrecht AM, et al
   The paracrine effects of fibroblasts on doxorubicin-treated breast cancer cells.
   Exp Cell Res. 2019 May 20. pii: S0014-4827(19)30261.
   PubMed     Text format     Abstract available
   
   
   
2. TAN S, Natasa B, Wong ESP, Lin VCL, et al
   Ligand-activated progesterone receptor B activates transcription factor EB to promote autophagy in human breast cancer cells MCF-7.
   Exp Cell Res. 2019 May 14. pii: S0014-4827(19)30255.
   PubMed     Text format     Abstract available
   
   
   April 2019
3. ZHOU R, Wang S, Wen H, Wang M, et al
   The bispecific antibody HB-32, blockade of both VEGF and DLL4 shows potent anti-angiogenic activity in vitro and anti-tumor activity in breast cancer xenograft models.
   Exp Cell Res. 2019 Apr 26. pii: S0014-4827(19)30209.
   PubMed     Text format     Abstract available
   
   
   
4. ZHANG ZG, Zhang HS, Sun HL, Liu HY, et al
   KDM5B promotes breast cancer cell proliferation and migration via AMPK-mediated lipid metabolism reprogramming.
   Exp Cell Res. 2019 Apr 9. pii: S0014-4827(19)30156.
   PubMed     Text format     Abstract available
   
   
   March 2019
5. LI D, Wang X, Yang M, Kan Q, et al
   miR3609 sensitizes breast cancer cells to adriamycin by blocking the programmed death-ligand 1 immune checkpoint.
   Exp Cell Res. 2019 Mar 20. pii: S0014-4827(19)30126.
   PubMed     Text format     Abstract available
   
   
   July 2018
6. CHEN JH, Kuo KT, Bamodu OA, Lin YC, et al
   Upregulated SCUBE2 expression in breast cancer stem cells enhances triple negative breast cancer aggression through modulation of notch signaling and epithelial-to-mesenchymal transition.
   Exp Cell Res. 2018 Jul 4. pii: S0014-4827(18)30398.
   PubMed     Text format     Abstract available
   
   
   May 2018
7. DING J, Xu Z, Zhang Y, Tan C, et al
   Exosome-mediated miR-222 Transferring: An insight into NF-kappaB-mediated Breast Cancer Metastasis.
   Exp Cell Res. 2018 May 17. pii: S0014-4827(18)30276.
   PubMed     Text format     Abstract available
   
   
   April 2018
8. ROYSTON KJ, Paul B, Nozell S, Rajbhandari R, et al
   Withaferin A and Sulforaphane Regulate Breast Cancer Cell Cycle Progression through Epigenetic Mechanisms.
   Exp Cell Res. 2018 Apr 21. pii: S0014-4827(18)30226.
   PubMed     Text format     Abstract available
   
   
   March 2018
9. LI C, Fan Q, Quan H, Nie M, et al
   The three branches of the unfolded protein response exhibit differential significance in breast cancer growth and stemness.
   Exp Cell Res. 2018 Mar 27. pii: S0014-4827(18)30183.
   PubMed     Text format     Abstract available
   
   
   
10. LI K, Yan H, Guo W, Tang M, et al
    ATM inhibition induces synthetic lethality and enhances sensitivity of PTEN-deficient breast cancer cells to cisplatin.
    Exp Cell Res. 2018 Mar 6. pii: S0014-4827(18)30125.
    PubMed     Text format     Abstract available
    
    
    
11. YAMASHITA N, Saito N, Zhao S, Terai K, et al
    Heregulin-induced cell migration is promoted by aryl hydrocarbon receptor in HER2-overexpressing breast cancer cells.
    Exp Cell Res. 2018 Mar 1. pii: S0014-4827(18)30116.
    PubMed     Text format     Abstract available
    
    
    January 2018
12. MOREIRA MP, da Conceicao Braga L, Cassali GD, Silva LM, et al
    STAT3 as a promising chemoresistance biomarker associated with the CD44(+/high)/CD24(-/low)/ALDH(+) BCSCs-like subset of the triple-negative breast cancer (TNBC) cell line.
    Exp Cell Res. 2018 Jan 15. pii: S0014-4827(18)30027.
    PubMed     Text format     Abstract available
    
    
    
13. HUANG Y, Yang L, Pei YY, Wang J, et al
    Overexpressed ACBD3 has prognostic value in human breast cancer and promotes the self-renewal potential of breast cancer cells by activating the Wnt/beta-catenin signaling pathway.
    Exp Cell Res. 2018 Jan 4. pii: S0014-4827(18)30003.
    PubMed     Text format     Abstract available
    
    
    
14. LUO CW, Wu CC, Chang SJ, Chang TM, et al
    CHD4-mediated loss of E-cadherin determines metastatic ability in triple-negative breast cancer cells.
    Exp Cell Res. 2018 Jan 3. pii: S0014-4827(17)30695.
    PubMed     Text format     Abstract available
    
    
    December 2017
15. GONG XF, Yu AL, Tang J, Wang CL, et al
    MicroRNA-630 inhibits breast cancer progression by directly targeting BMI1.
    Exp Cell Res. 2017 Dec 2. pii: S0014-4827(17)30640.
    PubMed     Text format     Abstract available
    
    
    November 2017
16. LO JH, Chen TT
    Production of bioactive recombinant human Eb-peptide of pro-IGF-I and identification of binding components from the plasma membrane of human breast cancer cells (MDA-MB-231).
    Exp Cell Res. 2017 Nov 27. pii: S0014-4827(17)30628.
    PubMed     Text format     Abstract available
    
    
    October 2017
17. ZHU S, Wang X, Wang J, Lin J, et al
    CD21lo/medCD27+ proinflammatory B cells are enriched in breast cancer patients and promote antitumor T cell responses.
    Exp Cell Res. 2017 Oct 17. pii: S0014-4827(17)30561.
    PubMed     Text format     Abstract available
    
    
    
18. DE S, Das S, Mukherjee S, Das S, et al
    Establishment of Twist-1 and TGFBR2 as direct targets of microRNA-20a in Mesenchymal to Epithelial Transition of Breast Cancer Cell-line MDA-MB-231.
    Exp Cell Res. 2017 Oct 4. pii: S0014-4827(17)30532.
    PubMed     Text format     Abstract available
    
    
    September 2017
19. CASCIONE M, De Matteis V, Toma CC, Pellegrino P, et al
    Morphomechanical and structural changes induced by ROCK inhibitor in breast cancer cells.
    Exp Cell Res. 2017 Sep 19. pii: S0014-4827(17)30500.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: